Compounds > simvastatin
Page last updated: 2024-08-23

simvastatin and Autosomal Dominant Juvenile Parkinson Disease

simvastatin has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cao, X; Chen, Z; Shi, Q; Tang, B; Wang, T; Zhang, T1
Brahmachari, S; Gendelman, HE; Ghosh, A; Matras, J; Pahan, K; Roy, A1
Chen, J; Deng, C; Hu, CH; Huang, XF; Long, L; Mackovski, N; Wang, Q; Wang, Y; Yang, Y; Zhu, C1
Gupta, A; Kalonia, H; Kumar, A; Mishra, J; Sharma, N1
Bezard, E; Dupouy, S; Galitzky, M; Li, Q; Marquine, L; Meissner, WG; Milhet, A; Nègre-Pagès, L; Ory-Magne, F; Rascol, O; Spampinato, U; Thiolat, ML; Thiollier, T; Tison, F1
McLachlan, C; Wang, PH; Wang, Q; Wong, PT1

Trials

1 trial(s) available for simvastatin and Autosomal Dominant Juvenile Parkinson Disease

ArticleYear
Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over ("n-of-1") exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients.
    Parkinsonism & related disorders, 2013, Volume: 19, Issue:4

    Topics: Adult; Aged; Animals; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Levodopa; Macaca; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Simvastatin

2013

Other Studies

5 other study(ies) available for simvastatin and Autosomal Dominant Juvenile Parkinson Disease

ArticleYear
Effect of simvastatin on L-DOPA-induced abnormal involuntary movements of hemiparkinsonian rats.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2015, Volume: 36, Issue:8

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Levodopa; Male; MAP Kinase Signaling System; Oncogene Proteins v-fos; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Simvastatin; Time Factors

2015
Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2009, Oct-28, Volume: 29, Issue:43

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Cell Survival; Disease Models, Animal; Dopamine; Humans; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neuroglia; Neurons; Neuroprotective Agents; Neurotransmitter Agents; NF-kappa B; Parkinson Disease; Parkinsonian Disorders; Pravastatin; Proto-Oncogene Proteins p21(ras); Simvastatin; Substantia Nigra

2009
Effects of simvastatin and 6-hydroxydopamine on histaminergic H1 receptor binding density in rat brains.
    Progress in neuro-psychopharmacology & biological psychiatry, 2010, Dec-01, Volume: 34, Issue:8

    Topics: Animals; Brain; Male; Oxidopamine; Parkinsonian Disorders; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Histamine H1; Simvastatin

2010
Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms.
    Brain research, 2012, Aug-30, Volume: 1471

    Topics: Amphetamine; Analysis of Variance; Animals; Atorvastatin; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Glutathione; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Male; Malondialdehyde; Mitochondria; Motor Activity; NADH Dehydrogenase; Nitrites; Oxidopamine; Parkinsonian Disorders; Pyrroles; Rats; Rats, Wistar; Simvastatin; Tetrazolium Salts; Thiazoles; Tumor Necrosis Factor-alpha

2012
Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats.
    Brain research, 2005, May-31, Volume: 1045, Issue:1-2

    Topics: Animals; Cognition Disorders; Disease Models, Animal; Down-Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medial Forebrain Bundle; Oxidopamine; Parkinsonian Disorders; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Recovery of Function; Simvastatin; Substantia Nigra; Sympatholytics; Treatment Outcome

2005